New combo therapy for breast cancer aims to outsmart drug resistance
NCT ID NCT07395336
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether combining two hormone-blocking drugs, elacestrant and exemestane, can help people with a certain type of advanced breast cancer (HR+/HER2-) that has stopped responding to initial treatments. The study uses a special PET scan to select participants whose tumors still have active estrogen receptors. The main goal is to see how long the cancer stays under control without growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elacestrant and exemestane (two hormone-blocking drugs)
What this could lead to
If successful, this could offer a new combination treatment option for certain patients with advanced breast cancer whose tumors still show estrogen receptors on PET scans.
What could go wrong
This is a small, early-phase study with only 26 participants. The combination may not work better than existing treatments, and side effects from the two drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
European Institute of Oncology
RECRUITINGMilan, Italy, 20141, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••